Background: Cerebral gray matter (GM) atrophy has clinical relevance in multiple sclerosis (MS). Fingolimod has known efficacy on clinical and conventional MRI findings in MS; the effect on GM is unknown.
A C C E P T E D M A N U S C R I P T
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple 
Introduction
MRI plays a key role in the clinical care and scientific investigation of multiple sclerosis (MS) [1, 2] .
Standard supportive outcome measures in clinical trials of MS disease-modifying therapies (DMTs) include MRI-defined cerebral lesions, such as gadolinium (Gd)-enhancing (Gd+) and T2 hyperintense lesions [3, 4] . In addition, MRI-based quantification of brain atrophy assesses the destructive aspects of the disease, which have been shown to be clinically relevant, and complementary to lesion measures [5] [6] [7] [8] [9] [10] . Facilitated by the increasing availability, sophistication, and efficiency of post-processing tools to quantify brain volume [11] [12] [13] [14] , whole brain atrophy assessment is a nearly ubiquitous supportive outcome in phase III MS clinical trials [9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Among the wide array of brain atrophy measures available, gray matter (GM) assessments are of growing interest in the field for several reasons. First, it is proposed that the GM is less prone to transient volume fluctuations due to edema, hydration status, inflammation, and pseudoatrophy as compared to the white matter (WM) compartment [25] [26] [27] [28] . Second, GM atrophy begins early in the disease process [5, 7, 25, 29] , even before the onset of MS symptoms [30] . Third, GM atrophy is associated with and predictive of a range of clinical manifestations of MS, such as physical disability, cognitive dysfunction, depression, and quality of life [7, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
Against this backdrop, several studies in the past ten years have explored the effect of DMTs on cerebral GM atrophy [9, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Fingolimod is an approved oral therapy for the treatment of relapsing-remitting (RR)
MS, based on its demonstrated effect in phase III trials [19, 52, 53] . In these trials, fingolimod showed a treatment effect on clinical relapses and MRI-defined lesions. An observational study also suggested an effect of fingolimod on limiting the rate of conversion from acute Gd+ lesions to chronic destructive lesions [54] . In addition, the pivotal phase III studies showed a partial but significant treatment effect on limiting the rate of whole brain atrophy, appearing as early as 6 months after the start of therapy [19, 52, 53] . The objective of this study was to explore the treatment effect of fingolimod on cerebral GM atrophy over two years in patients with relapsing forms of MS.
Material and Methods
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Subjects
Baseline demographic and clinical characteristics of the patients are summarized in Table 1 beta-1a (once a week, n = 14), subcutaneous interferon beta-1a (thrice weekly, n = 11), subcutaneous interferon beta-1b (on alternate days, n = 2), and intravenous natalizumab (monthly, n = 8). Each patient underwent examination by an MS specialist neurologist in order to evaluate the occurrence of relapses, Expanded Disability Status Scale (EDSS) scoring, and timed 25-foot walk (T25FW) within three months of the MRI.
In addition to the baseline measures shown in Table 1 , we also report disease activity measures in the two groups in the two years prior to study entry, as follows. Informed consent was not required because of the retrospective design of the study. This study was approved by our hospital's human research committee.
A C C E P T E D M
A N U S C R I P T Key: values are mean ± standard deviation (range) unless otherwise indicated; EDSS = Expanded Disability Status Scale score; cGMF = cortical gray matter fraction; BPF = brain parenchymal fraction; T2LV = cerebral T2 hyperintense lesion volume; Gd+ = cerebral gadolinium-enhancing lesion; †time since first symptoms; *p<0.05.
MRI acquisition
All subjects underwent baseline, one-year, and two-year follow-up brain MRI as part of routine clinical care on a fleet of 1.5T Signa scanners at our institution (General Electric, Milwaukee, WI). The MRI acquisition protocols were similar among subjects and time points, covering the whole brain and including an axial T2- All sequences were free of inter-slice gaps. In addition, the T1-weighted series was repeated 5-7 minutes after the intravenous infusion of single-dose Gd.
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Lesion analysis
MRI scans were manually traced from the T2-weighted conventional spin-echo dual-echo images using a semi-automated tool in Jim (v.7, Xinapse Systems Ltd., West Bergholt, UK; http://www.xinapse.com) to quantify whole brain T2 hyperintense lesion volume (T2LV) as previously described [58] . The number of cerebral Gd+ lesions was determined from the presence of enhancement on axial T1-weighted post-Gd images, concurrent with hyperintensity on the proton-density images. Our lesion measures have established high reliability as detailed previously [56] .
Statistical analysis
Baseline clinical and demographic comparisons were performed using t-tests or chi-squared tests as appropriate. The correlations between each of the baseline MRI measures and the other MRI, clinical and demographic measures were assessed using Pearson's correlation coefficients. The on-study change within subjects for cGMF, BPF, cube root transformed T2LV, EDSS and timed 25-foot walk was assessed using a mixed effects linear regression model with a random intercept and fixed effects for time, group and the time-bygroup interaction. Cube root transformations were analyzed for T2LV measures. For all analyses, time since the first MRI was used as the time metric, and a linear trend with time was assumed. The difference in the slope between the two groups was assessed using the interaction term. For the change in the number of Gd+ lesions, a mixed effects negative binomial regression model was used, and time was treated as a categorical variable. We used a categorical variable for time in this analysis since the number of Gd+ lesions at a scan describes the activity at that time point rather than the accumulation over an interval. Finally, the difference in the relapse rate comparing the two treatment groups was assessed using a negative binomial regression model. Our main null hypothesis that served as the basis for this study was that there was no difference between the treated and untreated in terms of change in MRI parameters over time. A p <0.05 was considered significant; a p >0.05 but < 0.10 was considered a trend towards significance. All statistical analysis was completed in the statistical package R (www.r-project.org) or Stata version 14.2.
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Results
Baseline characteristics
When comparing the two groups on baseline characteristics (Table 1) , there was a higher percentage of women (p=0.007) and a higher BPF (p=0.049) in the untreated group. The T2LV was higher in the fingolimod group (p=0.003; cube root transformed T2LV p=0.001). Otherwise, the two groups were similar at baseline.
When we assessed correlations among baseline MRI, clinical and demographic measures, many of the expected associations were observed (Table 2) . T2LV, BPF, and cGMF were significantly inter-correlated, and the strongest correlation was between cGMF and BPF. cGMF significantly correlated with age, and BPF was significantly associated with disease duration. No other clinical/demographic variables were associated with the MRI measures. 
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The on-study changes in cGMF are shown in Table 3 , and Figures 2 and 3. The untreated group showed a highly significant reduction in cGMF in the second year, and over the two years on-study (both p<0.001). In contrast, cGMF remained stable in the fingolimod group in the first and second year (both p>0.18) and showed a trend to increase over the two years of the study (p=0.083). Furthermore, the fingolimod group showed a significantly different rate of cortical GM atrophy over two years compared to the untreated group, and the difference between groups over two years was dominated by less cortical atrophy in the fingolimod group during the second year of observation. cGMF results were similar after adjusting for age and sex. Regarding the issue as to whether age might have been a confounding factor (as the Gilenya treated patients were somewhat younger than the untreated patients), Table 3 shows an analysis that adjusted for age and sex, with generally similar results in the unadjusted and adjusted analyses. Therefore, it is unlikely that the observed MRI findings were driven by group differences in age. When we restricted our analysis to subjects who had at least one Gd+ lesion at baseline, the findings were also similar (data not shown). Adjusted difference = the group difference is adjusted for age and sex; cGMF = cortical gray matter fraction; BPF = brain parenchymal fraction; T2LV = cerebral T2 hyperintense lesion volume (cube root transformed); EDSS = Expanded Disability Status Scale score; T25FW = timed 25-foot walk; *p<0.05.
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A N U S C R I P T The untreated group showed a highly significant reduction in cGMF in the second year, and over the two years on-study (both p<0.001, Table 3 ). In contrast, cGMF remained stable in the fingolimod group in the first and second year (p>0.05, Table 3 ). Furthermore, the fingolimod group showed a significantly lower rate of change in cGMF in both time periods than the untreated group (p<0.001, Table 3 ). Thus, the difference between groups over two years was dominated by the lack of cortical atrophy in the fingolimod group during the second year of observation.
Global cerebral atrophy
The on-study changes in BPF are shown in Table 3 and Figure 4 . BPF remained stable in the untreated group at all time points (all p>0.05). In contrast, the fingolimod group showed a significant reduction in BPF in the first year (p<0.05), and showed a trend towards significance for reduction over the full two years (p=0.06).
There were no significant differences between groups regarding the change in BPF in the first year, second year, or over the full two years on-study (all p>0.05). This finding persisted when adjusting for age and sex.
When only subjects with at least one Gd+ lesion were included in the analysis, BPF remained stable in the untreated group at all time points considered (all p>0.05). In contrast, BPF was significantly reduced over the full two years in the fingolimod group (p=0.03). The BPF change seen in this subgroup of fingolimod patients differed from the main findings when considering all patients. However, the between group differences in BPF change were not significant (all p>0.05) (data not shown). Table 3 ). In contrast, the fingolimod group showed a significant reduction in BPF in the first year (p<0.05, Table 3 ), and a trend towards significance for reduction over two years (p<0.10, Table 3 ). There were no significant differences between groups regarding the change in BPF in the first year, second year, or over the two years on-study (all p>0.05, Table 3 ).
Percent changes in cortical gray matter and whole brain fractions
In addition to the absolute changes shown in Table 3 
Cerebral T2 hyperintense lesions
The on-study changes in T2LV are shown in Tables 3 and Figure 5 . The untreated group showed a highly significant increase in T2LV over the two years on-study (p<0.001). In contrast, T2LV remained stable in the fingolimod group at all time points (all p≥0.44). Furthermore, the fingolimod group showed a 
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significantly lower rate of T2LV change over the two years on-study than the untreated group (p<0.001). In subjects with at least one Gd+ lesion, T2LV did not change in either group at any time point considered, and there were no significant differences between the groups in T2LV change (all p>0.05, data not shown). The untreated group showed a highly significant increase in T2LV over the two years on-study (p<0.001, Table  3 ). In contrast, T2LV remained stable in the fingolimod group at all time points (Table 3) . Furthermore, the fingolimod group showed a significantly lower rate of T2LV change over the two years on-study than the untreated group (p<0.001, Table 3 ).
Cerebral gadolinium-enhancing lesions
The on-study changes in Gd+ lesions are shown in Table 4 . The untreated group showed a significant decrease during the second year of the-study (p<0.05). The fingolimod group showed a significant decrease during the first year and over the two years of the study (both p<0.01). Comparing the two groups, Gd+ lesions decreased more in the fingolimod in the first year (p=0.001) and decreased more in the untreated group in the second year (p<0.05). Coefficients from mixed effects negative binomial regression model are reported. For the individual treatments, these can be converted to rate ratios comparing the two time points by exponentiating the coefficient; Adjusted difference = the group difference is adjusted for age and sex; Gd+ = cerebral gadolinium-enhancing lesions; *p<0.05.
On-study clinical change
When assessing the treatment effect of fingolimod on clinical measures, a significant difference in the change in the EDSS was observed over the two-year period between groups in both unadjusted and adjusted analyses (Table 3) . In both analyses, there was increased worsening of disability in the fingolimod group. A significant decrease in T25FW was observed within the fingolimod group in the first year (p<0.05) but not in the untreated group at any time point (all p>0.05). Between group differences in T25FW were only significant in the first year of observation (p<0.05) ( Table 3) . During the first year, patients in the fingolimod group had a higher relapse rate as compared to the untreated group (rate ratio=4.7, p=0.029). In contrast, in the second year, patients in the fingolimod group had a lower relapse rate even though the difference was not statistically significant between groups (rate ratio=0.70, p=0.63).
Discussion
The objective of the present study was to assess the treatment effect of fingolimod on cerebral GM atrophy over two years in patients with relapsing forms of MS. Our results show that over two years, cGMF remained stable in the fingolimod group but decreased in the untreated group; however, no significant differences were detected between groups in BPF change at any time point during the study period. Additional MRI analysis indicated that the fingolimod group showed a significantly lower rate of T2LV change over the two year study period than the untreated group and that the prevalence of Gd+ lesions significantly decreased over the two years in the fingolimod group, but only decreased in the untreated group during the second year of
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A C C E P T E D M A N U S C R I P T the study. These results demonstrate novel findings that suggest a treatment effect of fingolimod on brain atrophy that is not only detectable in the first two years after initiating therapy, but is selective to GM atrophy over whole brain atrophy. Although these results are promising, they should be considered preliminary due to the small sample size and the non-randomized, retrospective design of the study.
The results of the present study extend previous observations that have documented fingolimod's impact on brain atrophy. The pivotal phase III trials of fingolimod showed partial but significant treatment effects on limiting the rate of whole brain atrophy in patients with RRMS [19, 23, 52, 59] . For instance, in the FREEDOMS phase III clinical trial, 0.5 mg and 1.25 mg of fingolimod significantly reduced whole brain volume loss when compared to placebo [19] . Moreover, in the FREEDOMS II study, patients on fingolimod had a lower mean percent whole brain volume change (PBVC) when compared to placebo [23] . Likewise, in the TRANSFORMS study, a smaller percent reduction in brain volume from baseline to twelve months was seen in patients on fingolimod when compared to patients on interferon-beta [52] . Similarly, in the pooled post-hoc analysis of patients from two phase III studies (FREEDOMS I and FREEDOMS II), 0.5 mg of fingolimod significantly reduced PBVC over the period of twelve months and over two years when compared to placebo [59] . On the other hand, one previous study reported no significant difference in brain volume change when comparing patients on fingolimod to those on placebo [60] . Our results, with a much smaller sample size than the above-referenced studies, failed to demonstrate a significant difference in whole brain atrophy change between groups as well. This may have been on the basis of lack of power to detect such differences, given the small sample size of our study [61] . However, we detected a lower rate of GM atrophy in the fingolimod-treated vs. the untreated group in this study, in keeping with the observation that GM volume may provide more statistical power (requiring smaller sample sizes) to detect neurotherapeutic effects than whole brain volume [48, 61] . The lack of a group difference on BPF and the presence of a difference on the cGMF raises another possibility in addition to a power consideration. Namely, the difference on the WM compartment may have been present in the opposite direction. However, due to technical limitations of the source images (2D, low resolution, 1.5T) and segmentation results, we could not efficiently measure either the whole brain WM volume or deep central and posterior fossa GM volume in this study. Thus, we can only speculate on the explanation of
A C C E P T E D M A N U S C R I P T this divergence of results in our study, whether it reflected a technical effect or a biologic difference. Such definitive information may need to await studies with larger sample sizes and the availability of MR images at higher field strength with higher resolution 3D images.
MS has traditionally been defined as a WM disease, but mounting histopathological and neuroimaging data in the past several years have shown involvement of cerebral cortical and deep GM [62] [63] [64] [65] [66] . For instance, focal areas of demyelination, microglial proliferation, apoptotic neurons, atrophy and axonal injury are seen commonly in patients with MS [66] . Cerebral GM atrophy begins very early in the disease course [25, 67] , even before patients manifest their first MS symptoms [30] . Such atrophy is closely associated with physical disability and neuropsychological disability [14, 31, 32, 40, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] . GM may be less prone to transient volume fluctuations as compared to WM [26, 27] , providing a more sensitive and specific measure of neurodegeneration than whole brain volume [61] . Our findings are in keeping with these observations, that GM atrophy, assessed by MRI, may provide a sensitive tool to detect MS treatment effects.
The present study focused on the effect of fingolimod on GM atrophy and demonstrated that cortical volume (assessed by cGMF) remained stable in patients on fingolimod but decreased in untreated patients after two years. Assessments of the effects of MS therapies on GM atrophy have been implemented in several studies to date; however, the impact of fingolimod has not been previously determined. Previous studies have assessed the impact of other DMTs on cerebral GM atrophy and have yielded results similar to the present study [9, [42] [43] [44] [45] [46] [47] [48] [49] 51] . Patients on intramuscular interferon beta-1a (IFNβ-1a) showed a significant reduction in GM atrophy as compared to patients who elected not to receive therapy [51] . Another study demonstrated a significantly lower rate of GM atrophy in patients on IFNβ-1a vs. placebo in a phase III clinical trial [46] . Additionally, a study that compared IFNβ-1a or IFNβ-1b to glatiramer acetate demonstrated that patients on IFNβ-1a and IFN β-1b showed a significant reduction in GM volume after 24 months, whereas, patients on glatiramer acetate showed stability of GM volume [42] . Natalizumab showed protective effects on GM integrity in patients with progressive forms of MS [49] and no significant change in GM volume during one year of therapy in patients with RR or progressive forms of MS [47] . In a 3T high-resolution MRI study employing a fully automated image processing pipeline, dimethyl fumarate showed a treatment effect on GM atrophy appearing after one
A C C E P T E D M A N U S C R I P T year of therapy by demonstrating a significantly lower rate of putamen atrophy vs. untreated patients [44] .
Taken together, these results show the ability of DMTs to exert a partial but significant effect on limiting the rate of cerebral GM atrophy.
Numerous mechanisms have been proposed regarding the pathophysiology of GM atrophy in patients with MS, including direct formation of demyelinating plaques, microglial proliferation, leptomeningeal inflammation, anti-lipid antibodies, micro-RNAs, oxidative stress, and Wallerian degeneration [27, 44, 56, 57, [62] [63] [64] [65] [66] 75] . Understanding fingolimod's proposed mechanism of action may provide some explanation as to how this DMT impacts GM atrophy. Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator that has been shown to confer immunomodulatory effects and impact neuronal function [79] [80] [81] [82] . Upon entry into the CNS, fingolimod becomes phosphorylated and is able to bind, with high affinity, to four out of five S1P receptors, which are found on neural cells, astrocytes, and immune cells [80] [81] [82] [83] . Fingolimod conveys antiinflammatory effects by disrupting the normal flow of lymphocytes from the lymph nodes to areas of inflammation, may promote remyelination by impacting oligodendrocyte precursor cells, may enhance neurite growth by up-regulating immediate early genes, and may directly provide neuroprotective effects by antagonizing the apoptotic processes associated with neurodegeneration [79, 80-82, 84, 85] . Thus, one can speculate that fingolimod reduces GM atrophy either by its direct neuroprotective effect on neural cells via S1P receptor modulation or by its anti-inflammatory and immunomodulatory effects by sequestering lymphocytes in the lymphoid organs and preventing their recirculation to the CNS.
In addition to assessing fingolimod's impact on brain atrophy, the present study also explored group differences between treated and untreated patients on conventional MRI measures of lesions. In the present study, T2LV increased in the untreated group but remained stable in the fingolimod group over the period of two years. Previous studies have studied the impact of fingolimod on T2 lesions and have yielded similar results [19, 23, 52, [86] [87] [88] [89] [90] [91] [92] [93] [94] . Previous studies have also shown a treatment effect of fingolimod on limiting Gd+ lesions [19, 23, 52, 59, [86] [87] [88] [89] [90] [91] [92] [93] [94] . In the present study, a treatment effect of fingolimod vs. untreated patients on Gd+ lesions was seen in the first year but not in the second year. This discordant finding may be due to a variety of factors, such as the baseline mis-matching of patients (the untreated group had a lower number of Gd+ lesions
A C C E P T E D M A N U S C R I P T and lower T2LV at baseline and also had higher percentage of women [95, 96] ), the study design (small sample size and non-randomized comparison), or the known discordance between the development of lesions and atrophy in MS [8, 97] .
To measure neurologic impairment, the present study assessed overall physical disability (EDSS score) and ambulation time (T25FW). EDSS score decreased (improved disability) in the untreated group but increased in the fingolimod group. Similarly, we found that patients in the fingolimod group had a higher relapse rate in year one as compared to the untreated group. These clinical effects are opposite to the direction favoring fingolimod on GM atrophy effects in our study. This lack of effect on EDSS score and relapse rate disparity may be related to the fact that the untreated group had a lower number of Gd+ lesions and a lower T2LV at baseline as compared to the fingolimod group and that the fingolimod group had more male patients [95, 96] . Our results differed from most studies that have shown a treatment effect of fingolimod on progression of EDSS disability and relapse rates [19, 23, 86, 87, [89] [90] [91] [92] [93] [98] [99] [100] [101] . When assessing ambulation time, T25FW improved in year one in the fingolimod group but not in the untreated group. Similarly, a previous study, which measured multiple sclerosis functional composite (MSFC) z-scores (which include T25FW, 9-hole peg test, and a cognitive [paced auditory serial addition] test), demonstrated that MSFC z-scores remained stable or improved in the fingolimod group and worsened in the placebo group over a 24-month study period [19] .
Our study is not without major limitations and thus the findings should be considered preliminary. The sample size was small and the study design was a retrospective "real-world" open-label non-randomized therapy assignment. The two groups were not entirely matched on baseline characteristics. For example, patients in fingolimod group had a higher percentage of men, higher BPF, increased number of Gd+ lesions and T2LV at baseline vs. the untreated group. We thus need to acknowledge that a major weakness of our analysis is the two populations being compared. There may have been an inherent bias in retrospectively selecting an untreated population of MS patients for comparison to fingolimod treatment, as there may be confounding clinical characteristics that would lead a patient with MS to elect not to utilize treatment and/or a physician to not treat such a patient with DMT. While it can be assumed that any such biases would potentially have led to a slower rate of atrophy in the comparative population, this is only a presumption, and there are other factors that
A C C E P T E D M A N U S C R I P T could play in the other direction (prior refractory or progressive nature of their disease leaving patients to feel treatment is futile). Therefore ,we cannot exclude the possibility that our results could be artifactual due to the bias introduced by the heterogeneous characteristics between groups. In addition, more precise assessments of cerebral GM atrophy may be obtained in future studies with the availability of higher field (e.g. 3T) highresolution MRI acquisitions [102] (which were not available in the present study) and fully automated analysis pipelines [44, [103] [104] [105] . Furthermore, the availability of such higher field (e.g. 3T, 7T) high-resolution images would allow an important consideration of the role of any treatment effect on cortical lesions [43, 65, 106] or leptomeningeal inflammation [107, 108] that would correlate with or predict the treatment effect on cortical atrophy.
Conclusion:
Our results suggest an effect of fingolimod on cerebral GM atrophy in patients with RRMS over a period of 2 years. These findings also support the notion that GM atrophy is more sensitive to MS treatment effects than whole brain atrophy, EDSS score, or relapse rate. 
